AIML.CN AI/ML Innovations Inc. (CNQ): C$0.04 share, model projects upside to C$0.06

AIML.CN stock trades at C$0.04 on the CNQ exchange in Canada and shows low liquidity with volume 243600.00 versus average volume 415314.00. Investors tracking AI health plays should note the company reported EPS -0.03 and a negative PE of -1.33, highlighting continued losses while the business develops its AI/ML wearable and digital-health platform. This update connects recent price behaviour to fundamentals, technicals, and a model-led forecast to frame risk and a cautious opportunity set for short-term traders and long-term speculators.

Price and intraday snapshot

AIML.CN stock closed at C$0.04 with day low C$0.04 and day high C$0.04, showing a static session but above the 50-day average of C$0.037. Market cap sits at C$6730560.00 and shares outstanding are 168264000.00, underlining the company’s microcap status on CNQ.

Business model and sector context

AI/ML Innovations Inc. operates in Healthcare software and wearables focused on personal health monitoring using AI and ML, a niche inside the Healthcare sector. The healthcare sector in Canada is under pressure with average PE near 22.68, and AIML.CN’s valuation metrics differ sharply from sector peers, reflecting early-stage product commercialization and thin revenue per share of 0.000793904.

Financials and valuation

The company reports EPS -0.03, price-to-sales of 40.00 and price-to-book of 5.23, indicating a premium relative to reported revenue and minimal book value. Current ratio is 2.09 and cash per share is 0.005324, which shows short-term liquidity but persistent negative margins with net profit margin near -39.10%.

Technicals, liquidity and trading signals

Technicals show low momentum: RSI 40.70, ADX 14.53 (no clear trend) and OBV -3369524.00, consistent with weak directional volume. Relative liquidity is limited given average volume 415314.00 and today’s volume 243600.00, increasing execution risk for larger orders.

Meyka AI grade and model forecast

Meyka AI rates AIML.CN with a score out of 100: 58.25 / 100 — Grade C+ (HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly C$0.01 and yearly C$0.02 versus the current price C$0.04, implying downside in the baseline model but room for upside if commercialization accelerates. Forecasts are model-based projections and not guarantees.

Catalysts and risks for AI stock investors

Near-term catalysts include regulatory approvals, pilot program wins with care providers, and revenue conversion from the patent-pending monitoring system. Primary risks are limited revenues, stretched valuation ratios, thin liquidity and a company-level rating recently flagged as C- / Strong Sell by a third-party on 2026-02-04, which increases downside risk for retail investors. See sector comparisons for peer context source and competitor listing source.

Final Thoughts

Key takeaways for AIML.CN stock: the share price rests at C$0.04 on CNQ with microcap liquidity and a market cap of C$6730560.00, reflecting an early-stage AI health software play with negative earnings and thin revenue. Valuation ratios such as price-to-sales 40.00 and price-to-book 5.23 underline a mismatch between market price and reported fundamentals. Meyka AI’s forecast model projects a baseline yearly value near C$0.02, while our scenario price targets assume a base-case C$0.06 (implied upside 50.00%), bull C$0.12 (implied upside 200.00%) and bear C$0.02 (implied downside -50.00%). These targets reflect product adoption, pilot conversions, and typical microcap volatility. Investors should treat AIML.CN as speculative, weigh execution risk and low liquidity, and use position sizing consistent with a high-risk AI stocks strategy. Meyka AI provides this as an AI-powered market analysis platform; forecasts are model-based and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.